WO2001010846A3 - 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system - Google Patents

1,4-diazepine derivatives for the treatment of diseases related to the central nervous system Download PDF

Info

Publication number
WO2001010846A3
WO2001010846A3 PCT/CA2000/000897 CA0000897W WO0110846A3 WO 2001010846 A3 WO2001010846 A3 WO 2001010846A3 CA 0000897 W CA0000897 W CA 0000897W WO 0110846 A3 WO0110846 A3 WO 0110846A3
Authority
WO
WIPO (PCT)
Prior art keywords
central nervous
nervous system
compounds
treatment
diseases related
Prior art date
Application number
PCT/CA2000/000897
Other languages
French (fr)
Other versions
WO2001010846A2 (en
Inventor
Kenneth Curry
Hossien Pajouhesh
Original Assignee
Igt Pharma Inc
Kenneth Curry
Hossien Pajouhesh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igt Pharma Inc, Kenneth Curry, Hossien Pajouhesh filed Critical Igt Pharma Inc
Priority to AU64207/00A priority Critical patent/AU6420700A/en
Priority to JP2001515312A priority patent/JP2003506440A/en
Priority to MXPA02001340A priority patent/MXPA02001340A/en
Priority to CA002381260A priority patent/CA2381260A1/en
Priority to EP00951157A priority patent/EP1210338A2/en
Publication of WO2001010846A2 publication Critical patent/WO2001010846A2/en
Publication of WO2001010846A3 publication Critical patent/WO2001010846A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to therapeutically active novel 1,4-benzodiazepine compounds and derivatives thereof, of formula (I), wherein R31 or/and R32 contain at least a carboxy, or an amino group or both. Also provided is a method of preparing compounds of formula (I), and pharmaceutical compositions comprising the compounds. The novel compounds act as modulators of metabotropic glutamate receptors and, as such, are useful in treating diseases of the central nervous system related to the metabotropic glutamate receptor system.
PCT/CA2000/000897 1999-08-05 2000-08-04 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system WO2001010846A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU64207/00A AU6420700A (en) 1999-08-05 2000-08-04 Novel 1,4-benzodiazepine compounds and derivatives thereof
JP2001515312A JP2003506440A (en) 1999-08-05 2000-08-04 1,4-Diazepine derivatives for the treatment of diseases associated with the central nervous system
MXPA02001340A MXPA02001340A (en) 1999-08-05 2000-08-04 Novel 1,4-benzodiazepine compounds and derivatives thereof.
CA002381260A CA2381260A1 (en) 1999-08-05 2000-08-04 Novel 1,4-benzodiazepine compounds and derivatives thereof
EP00951157A EP1210338A2 (en) 1999-08-05 2000-08-04 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA2,279,689 1999-08-05
CA2279689 1999-08-05
CA2299477 2000-02-24
CA2,299,477 2000-02-24

Publications (2)

Publication Number Publication Date
WO2001010846A2 WO2001010846A2 (en) 2001-02-15
WO2001010846A3 true WO2001010846A3 (en) 2001-11-08

Family

ID=25681103

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/000897 WO2001010846A2 (en) 1999-08-05 2000-08-04 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system

Country Status (5)

Country Link
EP (1) EP1210338A2 (en)
JP (1) JP2003506440A (en)
AU (1) AU6420700A (en)
MX (1) MXPA02001340A (en)
WO (1) WO2001010846A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8841323B2 (en) 2006-03-15 2014-09-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8906939B2 (en) 2007-03-07 2014-12-09 Janssen Pharmaceuticals, Inc. 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9085577B2 (en) 2009-05-12 2015-07-21 Janssen Pharmaceuticals, Inc. 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500260A (en) 2001-04-02 2005-01-06 ブラウン ユニバーシティ リサーチ ファウンデイション Compositions and methods of use of mGluR5 antagonists
US6916821B2 (en) 2001-04-02 2005-07-12 Brown University Methods of treating disorders with Group I mGluR antagonists
NZ528315A (en) * 2001-04-12 2005-04-29 F Dihydro-benzo [b] [1, 4] diazepin-2-one derivatives as MGLUR2 antagonists II
CN1268626C (en) 2001-04-12 2006-08-09 弗·哈夫曼-拉罗切有限公司 Dihydro-benzo(b)(1,4)diazepin-2-one derivatives as mglur2 antagonists I
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
DE602005008095D1 (en) 2004-11-05 2008-08-21 Hoffmann La Roche PROCESS FOR THE PREPARATION OF ISONICOTINIC ACID DERIVATIVES
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
CN101657432B (en) 2007-04-19 2013-04-10 弗·哈夫曼-拉罗切有限公司 Dihydro-benzo[B][1,4]diazepin-2-one sulfonamide derivatives
JP2010526825A (en) 2007-05-10 2010-08-05 エーエムアール テクノロジー インコーポレイテッド Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and their use to block reuptake of norepinephrine, dopamine and serotonin
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
DK3431106T3 (en) 2014-01-21 2021-03-15 Janssen Pharmaceutica Nv COMBINATIONS INCLUDING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROP GLUTAMATERG SUBTYPE 2 RECEPTOR AND USE OF THESE
ES2860298T3 (en) 2014-01-21 2021-10-04 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators of metabotropic glutamatergic receptor subtype 2 and their use
US11198699B2 (en) 2019-04-02 2021-12-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5
CN112574220B (en) * 2020-12-08 2022-10-11 北京工业大学 Chiral heterocyclic compound and preparation method thereof
CN112851691B (en) * 2021-01-27 2022-10-11 北京工业大学 Chiral oxadiazine heterocyclic compound and preparation method thereof

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1391081A (en) * 1971-03-17 1975-04-16 Crc Ricerca Chim Optically active benzodiazepines
US3915961A (en) * 1972-12-21 1975-10-28 American Home Prod 5-Aryl-1H-1,4-benzodiazepine-2(3H)-one-3-phosphonic acids, derivatives and processes for their use
EP0264797A2 (en) * 1986-10-24 1988-04-27 Abbott Laboratories Benzodiazepines assay, tracers, immunogens and antibodies
EP0284256A1 (en) * 1987-03-16 1988-09-28 Merck & Co. Inc. Benzodiazepine analogs
EP0434364A2 (en) * 1989-12-18 1991-06-26 Merck & Co. Inc. Benzodiazepine analogs for treating panic syndrome and for directly inducing analgesia
DE4000768A1 (en) * 1990-01-12 1991-07-18 Bayer Ag Storage stable agent for treating e.g. Alzheimer's dementia - comprises hydrated 7-chloro-5-phenyl-spiro(1H-1,4-benzodiazepine-3 4'-piperidin)-2(3H)-one hydrochloride
JPH04202186A (en) * 1990-11-30 1992-07-22 Dainabotsuto Kk 1-or 3-substituted clonazepam derivative
WO1993019052A1 (en) * 1992-03-24 1993-09-30 Merck Sharp & Dohme Limited 3-ureido substituted benzodiazepin-2-ones having cholecystokinin and/or gastrin antagonistic activity and their use in therapy
WO1995006041A1 (en) * 1993-08-25 1995-03-02 Yamanouchi Pharmaceutical Co. Ltd. 3-phenylureido-1,4-benzodiazepines useful as selective cck-b antagonists
EP0645378A1 (en) * 1993-09-24 1995-03-29 Takeda Chemical Industries, Ltd. Condensed seven- or eight-membered heterocyclic compounds useful as squalene synthetase inhibitors
JPH07304755A (en) * 1994-05-12 1995-11-21 Yamanouchi Pharmaceut Co Ltd Condensed diazepine derivative
EP0705607A2 (en) * 1994-10-07 1996-04-10 Takeda Chemical Industries, Ltd. Condensed seven- or eight-membered heterocyclic compounds useful as antihypertriglyceridemic agents
WO1998028268A2 (en) * 1996-12-23 1998-07-02 Elan Pharmaceuticals, Inc. CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS
WO1998038177A1 (en) * 1997-02-28 1998-09-03 Elan Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AND THEIR USE FOR INHIBITING β-AMYLOID PEPTIDE
WO1999019306A2 (en) * 1997-10-10 1999-04-22 Board Of Regents, The University Of Texas System 2,3-benzodiazepin-2-one derivatives, their preparation and their use as inhibitors of protein tyrosine kinases
WO1999026927A2 (en) * 1997-11-21 1999-06-03 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases
WO2000069836A1 (en) * 1999-05-14 2000-11-23 Glaxo Group Limited Short-acting benzodiazepines

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1391081A (en) * 1971-03-17 1975-04-16 Crc Ricerca Chim Optically active benzodiazepines
US3915961A (en) * 1972-12-21 1975-10-28 American Home Prod 5-Aryl-1H-1,4-benzodiazepine-2(3H)-one-3-phosphonic acids, derivatives and processes for their use
EP0264797A2 (en) * 1986-10-24 1988-04-27 Abbott Laboratories Benzodiazepines assay, tracers, immunogens and antibodies
EP0284256A1 (en) * 1987-03-16 1988-09-28 Merck & Co. Inc. Benzodiazepine analogs
EP0434364A2 (en) * 1989-12-18 1991-06-26 Merck & Co. Inc. Benzodiazepine analogs for treating panic syndrome and for directly inducing analgesia
DE4000768A1 (en) * 1990-01-12 1991-07-18 Bayer Ag Storage stable agent for treating e.g. Alzheimer's dementia - comprises hydrated 7-chloro-5-phenyl-spiro(1H-1,4-benzodiazepine-3 4'-piperidin)-2(3H)-one hydrochloride
JPH04202186A (en) * 1990-11-30 1992-07-22 Dainabotsuto Kk 1-or 3-substituted clonazepam derivative
WO1993019052A1 (en) * 1992-03-24 1993-09-30 Merck Sharp & Dohme Limited 3-ureido substituted benzodiazepin-2-ones having cholecystokinin and/or gastrin antagonistic activity and their use in therapy
WO1995006041A1 (en) * 1993-08-25 1995-03-02 Yamanouchi Pharmaceutical Co. Ltd. 3-phenylureido-1,4-benzodiazepines useful as selective cck-b antagonists
EP0645378A1 (en) * 1993-09-24 1995-03-29 Takeda Chemical Industries, Ltd. Condensed seven- or eight-membered heterocyclic compounds useful as squalene synthetase inhibitors
JPH07304755A (en) * 1994-05-12 1995-11-21 Yamanouchi Pharmaceut Co Ltd Condensed diazepine derivative
EP0705607A2 (en) * 1994-10-07 1996-04-10 Takeda Chemical Industries, Ltd. Condensed seven- or eight-membered heterocyclic compounds useful as antihypertriglyceridemic agents
WO1998028268A2 (en) * 1996-12-23 1998-07-02 Elan Pharmaceuticals, Inc. CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS
WO1998038177A1 (en) * 1997-02-28 1998-09-03 Elan Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AND THEIR USE FOR INHIBITING β-AMYLOID PEPTIDE
WO1999019306A2 (en) * 1997-10-10 1999-04-22 Board Of Regents, The University Of Texas System 2,3-benzodiazepin-2-one derivatives, their preparation and their use as inhibitors of protein tyrosine kinases
WO1999026927A2 (en) * 1997-11-21 1999-06-03 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases
WO2000069836A1 (en) * 1999-05-14 2000-11-23 Glaxo Group Limited Short-acting benzodiazepines

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ICHIHARA, MASATO ET AL: "Preparation of diazepine derivatives as specific inhibitors of human renin", XP002172523, retrieved from STN Database accession no. 124:232494 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KANEHIRO, MASAHIKO ET AL: "Preparation of 1- or 3-substituted chlonazepam derivatives as haptens and antigens for immunoassay of chlonazepam", XP002172524, retrieved from STN Database accession no. 118:101995 *
J.SCHMITT, M.BRUNAUD: "Sur de nouvelles benzodiazépines hydrosolubles douées d'une puissante activité sur le système nerveux central", CHIMIE THÉRAPEUTIQUE, vol. 4, 1969, pages 239 - 245, XP002164835 *
MANGHISI E ET AL: "SYNTHESIS AND CENTRAL NERVOUS EFFECTS OF SOME 3-SUBSTITUTED-1,4- BENZODIAZEPIN-2-ONES", BOLLETTINO CHIMICO FARMACEUTICO,SOCIETA EDITORIALE FARMACEUTICA, MILANO,IT, vol. 113, no. 12, December 1974 (1974-12-01), pages 642 - 644, XP000944931, ISSN: 0006-6648 *
SHIMAMOTO K ET AL: "PHARMACOLOGICAL SCREENING OF NEW BANZODIAZEPINES IN MICE", TAKEDA KENKYUSHO HO - JOURNAL OF THE TAKEDA RESEARCH LABORATORIES,OSAKA,JP, vol. 29, no. 1, 1970, pages 134 - 144, XP000965475, ISSN: 0371-5167 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266834B2 (en) 2006-03-15 2016-02-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8841323B2 (en) 2006-03-15 2014-09-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8906939B2 (en) 2007-03-07 2014-12-09 Janssen Pharmaceuticals, Inc. 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
US9132122B2 (en) 2007-09-14 2015-09-15 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9085577B2 (en) 2009-05-12 2015-07-21 Janssen Pharmaceuticals, Inc. 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9226930B2 (en) 2009-05-12 2016-01-05 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors

Also Published As

Publication number Publication date
EP1210338A2 (en) 2002-06-05
AU6420700A (en) 2001-03-05
MXPA02001340A (en) 2004-07-16
JP2003506440A (en) 2003-02-18
WO2001010846A2 (en) 2001-02-15

Similar Documents

Publication Publication Date Title
WO2001010846A3 (en) 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system
MXPA02011053A (en) Novel spiro[2.4]heptane amino carboxy compounds and derivatives thereof.
HU9602522D0 (en) Heterocyclic compounds, their preparation and use
EP1595871A3 (en) Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
WO1999026927A3 (en) Metabotropic glutamate receptor antagonists for treating central nervous system diseases
WO2004014881A3 (en) '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
CA2216796A1 (en) Quinazoline derivatives
WO1997020823A3 (en) 2-amino quinazoline derivatives as npy receptor antagonists
MXPA02010405A (en) Novel amino carboxy alkyl derivatives of barbituric acid.
BR9910130A (en) Cuban derivatives as metabotropic glutamate receptor antagonists and process for their preparation
AU4629796A (en) 5-(4-subst.-piperidinyl-1)-3-aryl-pentanoic acid derivatives as tachykinin receptor antagonist
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
AU6611696A (en) N-(4-substituted-benzyl)-2-aminolactam derivatives
CA2282279A1 (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
MXPA02000242A (en) 2-aminoindane analogs.
CA2296560A1 (en) Amino acid derivatives useful to treat stroke
GR3034354T3 (en) IMIDAZO 1,2-a]QUINOXALIN-4-AMINES ACTIVE AS ADENOSINE ANTAGONISTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
WO2001002340A3 (en) Novel aminoindanes
AU5334196A (en) Method for the preparation of esters of anhydroecgonine
MX9804631A (en) Quinazoline-4-one ampa antagonists.
MX9801192A (en) Novel opioid peptides.
MX9703610A (en) Novel 2,3 disubstituted-(5,6)-heteroarylfused-pyrimidine-4-ones.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2381260

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 64207/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/001340

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000951157

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000951157

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10049092

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000951157

Country of ref document: EP